Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in People With Cystic Fibrosis and at Least One F508del Allele: 144-Week Interim Results From a 192-Week Open-label Extension Study

AIMS: In two pivotal Phase 3 trials, up to 24 weeks of treatment with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious and safe in patients with cystic fibrosis

• Daines, C. L.
• Tullis, E.
• Costa, S.
• Linnemann, R. W.
• Mall, M. A.
• McKone, E. F.
• Polineni, D.
• Quon, B. S.
• Ringshausen, F. C.
• Rowe, S. M.
• Selvadurai, H.
• Taylor-Cousar, J. L.
• Withers, N. J.
• Ahluwalia, N.
• Moskowitz, S. M.
• Prieto-Centurion, V.
• Tan, Y. V.
• Tian, S.
• Weinstock, T.
• Xuan, F.
• Zhang, Y.
• Ramsey, B.
• Griese, M.